Recently, we found that co-targeting CDK2, CDK6, and ER signaling inhibits the growth of ER+/HER2− breast cancer cells resistant to combined CDK4/6i and ET [24], supporting the use of this triple combination as a novel therapeutic strategy. Here, ESR1 is linked to breast cancer.